AbbVie says global Humira market eroding faster than expected

AbbVie Inc. (NYSE:ABBV) Chairman and CEO Richard Gonzalez said the company now expects greater erosion in ex-U.S. sales of autoimmune drug Humira adalimumab by the end of next year than previously guided. During the pharma’s 3Q18 earnings conference call Friday, Gonzalez said AbbVie now expects an erosion rate of 26-27% in 2019. It previously expected 18-20% erosion over 2018-20.